Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate

Author:

Chan Ho Sze,Konijnenberg Mark W.,de Blois Erik,Koelewijn Stuart,Baum Richard P.,Morgenstern Alfred,Bruchertseifer Frank,Breeman Wouter A.,de Jong Marion

Funder

DINSE Stiftung

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging

Reference34 articles.

1. Bodei L, Kidd M, Baum RP, Modlin IM. PRRT: defining the paradigm shift to achieve standardization and individualization. J Nucl Med. 2014;55(11):1753–6. Epub 2014/09/27.

2. van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ. Gepnets update: radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol. 2015;172(1):R1–8. Epub 2014/08/15.

3. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med. 2005;46 Suppl 1:199S–204. Epub 2005/01/18.

4. Morgenstern A, Bruchertseifer F, Apostolidis C. Targeted alpha therapy with 213Bi. Curr Radiopharm. 2011;4(4):295–305. Epub 2011/12/29.

5. Jurcic JG, Caron PC, Nikula TK, Papadopoulos EB, Finn RD, Gansow OA, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. 1995;55(23 Suppl):5908s–10. Epub 1995/12/01.

Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient;The Journal of Clinical Endocrinology & Metabolism;2024-04-23

2. Efficacy and Safety of 225Ac-DOTATATE in the Treatment of Neuroendocrine Neoplasms With High SSTR Expression;Clinical Nuclear Medicine;2024-03-18

3. Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review;Pharmaceuticals;2024-03-04

4. A Tree Can Be Recognized by Its Fruit;Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum;2024

5. Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors;European Journal of Nuclear Medicine and Molecular Imaging;2023-11-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3